Age (y) | 71 | 50–87 |
Time since diagnosis of prostate cancer (y) | 8 | 2–17 |
Gleason score | 8 | 6–10 |
Alkaline phosphatase (U/L) | 131 | 49−1,896 |
Hemoglobin (g/L) | 117 | 88–151 |
Lactate dehydrogenase (U/L) | 268 | 148–1,331 |
PSA (ng/mL) | 189.8 | 7–4,022 |
PSA doubling time (mo) | 2.3 | −5.8 to 22.9 |
Eastern Cooperative Oncology Group performance status | | |
0 | 20 (40%) | |
1 | 22 (44%) | |
2 | 8 (16%) | |
Prior therapies | | |
Abiraterone or enzalutamide or both | 46 (92%) | |
Docetaxel | 42 (84%) | |
Cabazitaxel | 24 (48%) | |
Docetaxel + enzalutamide/abiraterone ± cabazitaxel | 39 (78%) | |
Stage of disease (68Ga-PSMA-11 PET) | | |
Node only (M1a) | 2 (4%) | |
Bone (M1b) | 38 (76%) | |
Visceral (M1c) | 10 (20%) | |
Pain at baseline (BPI pain severity score) | | |
None (<1) | 8 (16%) | |
Mild (1–4) | 29 (58%) | |
Moderate to severe (5–10) | 13 (26%) | |